The Fat-Loss Shot Stack That Could Replace Ozempic: Retatrutide + Cagrilintide Explained

Key Takeaways

• Retatrutide is a triple-hormone agonist (GLP-1/GIP/glucagon) showing record-breaking fat-loss results in clinical trials.

• Cagrilintide is an amylin analog that enhances satiety and may complement GLP drugs.

• Combined, they could form a next-gen weight loss injections stack,  targeting appetite, metabolism, and energy expenditure.

• Early data suggest this duo may surpass Ozempic® (semaglutide) in both speed and magnitude of results.

• Both drugs are still under investigation; safety, dosing, and FDA approval are pending.
  
  

  What Is Retatrutide?

  Retatrutide (LY3437943) is Eli Lilly’s experimental triple-agonist drug that activates:

  1. GLP-1 (Glucagon-like peptide-1) – reduces appetite and slows digestion

  2. GIP (Glucose-dependent insulinotropic peptide) – enhances insulin sensitivity

  3. Glucagon receptor – increases fat metabolism and energy expenditure

  In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction—rivaling or even surpassing bariatric surgery outcomes.
  
  

  What Is Cagrilintide?

  Cagrilintide (NN00739) is a synthetic analog of amylin, a hormone released with insulin that promotes satiety and slows gastric emptying.

  It works differently from GLP-1 drugs, acting as a complementary mechanism:

  • Increases fullness signals to the brain

  • Decreases cravings and meal frequency

  • Helps sustain steady blood-sugar control

  Cagrilintide has been studied both as a solo treatment and in combination with semaglutide, showing synergistic weight-loss effects beyond either alone.
  
  

  The Science Behind the “Fat-Loss Shot Stack”

  Researchers are now exploring the potential synergy between Retatrutide + Cagrilintide, combining GLP-1/GIP/glucagon activation with amylin signaling for multi-pathway fat loss.

  This stack could theoretically:

  • Suppress appetite more effectively than semaglutide

  • Enhance calorie burn via glucagon activation

  • Preserve lean mass while reducing fat mass

  • Stabilize hunger hormones for long-term maintenance

  In early data and preclinical models, this combination produced unprecedented fat-loss percentages, suggesting a paradigm shift in obesity medicine.

  
  How Does It Compare to Ozempic®?
  

  Benefits & Considerations

  Potential Benefits:

  • Greater total fat loss

  • Reduced hunger and cravings

  • Possible metabolic improvements beyond semaglutide

  • May help maintain results long-term

  Considerations:

  • Not yet FDA-approved

  • Side effects may overlap (nausea, constipation, fatigue)

  • Long-term safety data still limited